NCT04407143 (SOLID) is a clinical trial of IgG test in Lung Cancer, sponsored by Fundación GECP.

Who is sponsoring NCT04407143?

NCT04407143 is sponsored by Fundación GECP.

What drugs are being tested in NCT04407143?

Interventions in NCT04407143: IgG test.

What condition does NCT04407143 study?

NCT04407143 studies Lung Cancer, COVID, Corona Virus Infection.

Is NCT04407143 still recruiting?

NCT04407143 is currently completed. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT04407143: SOLID

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Immunity of Patients With Lung Cancer and COVID-19 Infection

Completed Last updated 9 February 2026

What this trial tests

trial testing IgG test in Lung Cancer in 1,980 participants. Completed in 30 May 2022.

Timeline

15 April 2020

Primary endpoint
30 April 2022

30 May 2022

Quick facts

Lead sponsor	Fundación GECP
Status	Completed
Study type	OBSERVATIONAL
Enrollment	1,980
Start date	15 April 2020
Primary completion	30 April 2022
Estimated completion	30 May 2022
Sites	68 locations across Spain

Drugs / interventions tested

IgG test

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
COVID — all drugs for COVID →
Corona Virus Infection — all drugs for Corona Virus Infection →

Sponsor

Fundación GECP — full company profile →

Who can join

18 and older, any sex, with Lung Cancer or COVID. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Observational, retrospective data collection and prospective IgG analysis, and multicenter study. The main objective of the study is th description of the characteristics and evolution of patients with lung cancer who have acquired COVID-19 infection. For the identification of patients who contract COVID-19 infection, the IgG+ blood test by ELISA method will be used.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?
Vivarelli S, Falzone L, Grillo CM, Scandurra G, et al · · 2020 · cited 63× · PMID 32785162 · DOI 10.3390/cancers12082237
Immunogenicity of COVID-19 vaccines in lung cancer patients.
Provencio M, Estival A, Franco F, López-Vivanco G, et al · · 2023 · cited 8× · PMID 37639820 · DOI 10.1016/j.lungcan.2023.107323
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.
Provencio M, Rodríguez-Abreu D, Ortega AL, Serrano G, et al · · 2022 · cited 5× · PMID 35242627 · DOI 10.21037/tlcr-21-504
Immunogenicity of COVID‑19 Vaccines in Lung Cancer Patients: A SOLID Substudy Interim Analysis
Provencio M, Estival A, Franco F, López-Vivanco G, et al · · 2021 · DOI 10.2139/ssrn.3978650

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Fundación GECP trials

Trials by the same sponsor.

NCT07247786 — Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI · Phase 2 · not yet recruiting
NCT07242547 — Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients · Phase 2 · recruiting
NCT06917573 — PALACE: Cemiplimab Trial According to ctDNA Levels · Phase 2 · recruiting
NCT07153445 — Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lu · Phase 2 · recruiting
NCT06431633 — Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04407143 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación GECP
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04407143.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing